Biosimilar filgrastim vs filgrastim: A multicenter nationwide observational bioequivalence study in patients with chemotherapy-induced neutropenia by Sevinç, A. et al.
© 2018 Sevinç et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php 
and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you 
hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission 
for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
OncoTargets and Therapy 2018:11 419–426
OncoTargets and Therapy Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
419
O r i g i n a l  r e s e a r c h
open access to scientific and medical research
Open access Full Text article
http://dx.doi.org/10.2147/OTT.S106342
Biosimilar filgrastim vs filgrastim: a multicenter 
nationwide observational bioequivalence study in 
patients with chemotherapy-induced neutropenia
alper sevinç,1 Metin Özkan,2 
ahmet Özet,3 Faysal Dane,4 
Berna Öksüzog˘lu,5 
Abdurrahman Işıkdog˘an,6 
Feyyaz Özdemir,7 Dog˘an 
Uncu,8 Mahmut Gümüş,9 
Türkkan evrensel,10 arzu 
Yaren,11 Og˘uz Kara,12 salim 
Başol Tekin13
1Department of Medical Oncology, Medical 
Park gaziantep hospital, gaziantep, 
2Department of Medical Oncology, erciyes 
University Faculty of Medicine, Kayseri, 
3Department of Medical Oncology, gazi 
University Faculty of Medicine, ankara, 
4Department of Medical Oncology, 
Marmara University Faculty of Medicine, 
istanbul, 5Department of Medical Oncology, 
Dr abdurrahman Yurtaslan ankara 
Oncology Training and research hospital, 
ankara, 6Department of Medical Oncology, 
Dicle University Faculty of Medicine, 
Diyarbakır, 7Department of Medical 
Oncology, Karadeniz Technical University 
Faculty of Medicine, Trabzon, 8Department 
of Medical Oncology, ankara numune 
hospital, ankara, 9Department of Medical 
Oncology, istanbul Medeniyet University, 
istanbul, 10Department of Medical 
Oncology, Uludag˘ University Faculty of 
Medicine, Bursa, 11Department of Medical 
Oncology, Pamukkale University Faculty of 
Medicine, Denizli, 12Department of Medical 
Oncology, Çukurova University Faculty of 
Medicine, adana, 13Department of Medical 
Oncology, atatürk University Faculty of 
Medicine, erzurum, Turkey
Background: We studied the comparative effectiveness of biosimilar filgrastim vs original 
filgrastim in patients with chemotherapy-induced neutropenia.
Patients and methods: This multicenter, observational study was conducted at 14 centers. The 
study included 337 patients experiencing neutropenia under chemotherapy. Patients were given 
either filgrastim 30 MIU or 48 MIU (Neupogen®) or biosimilar filgrastim 30 MIU (Leucostim®). 
Data regarding age, chemotherapeutic agents used, number of chemotherapy courses, previous 
diagnosis of neutropenia, neutrophil count of patients after treatment, medications used for the 
treatment of neutropenia, and duration of neutropenia were collected. Time to absolute neutrophil 
count (ANC) recovery was the primary efficacy measure.
Results: Ambulatory and hospitalized patients comprised 11.3% and 45.1% of the enrolled 
patients, respectively, and a previous diagnosis of neutropenia was reported in 49.3% of the 
patients, as well. Neutropenia occurred in 13.7% (n=41), 45.5% (n=136), 27.4% (n=82), 11.4% 
(n=34), and 2.0% (n=6) of the patients during the first, second, third, fourth, and fifth cycles of 
chemotherapy, respectively. While the mean neutrophil count was 0.53±0.48 before treatment, 
a significant increase to 2.44±0.66 was observed after treatment (p=0.0001). While 90.3% of 
patients had a neutrophil count ,1.49 before treatment, all patients had a neutrophil count $1.50 
after treatment. Neutropenia resolved within #4 days of filgrastim therapy in 60.1%, 56.7%, 
and 52.6% of the patients receiving biosimilar filgrastim 30 MIU, original filgrastim 30 MIU, 
and original filgrastim 48 MIU, respectively. However, there was no significant difference 
between the three arms (p=0.468). Similarly, time to ANC recovery was comparable between 
the treatment arms (p=0.332).
Conclusion: The results indicate that original filgrastim and biosimilar filgrastim have comparable 
efficacy in treating neutropenia. Biosimilar filgrastim provides a valuable alternative; however, 
there is need for further studies comparing the two products in different patient subpopulations.
Keywords: chemotherapy, febrile neutropenia, neutrophil, ANC recovery, supportive care, 
myelosuppressive
Introduction
Despite improvements in supportive care, neutropenia and its complications remain a major 
issue for patients receiving myelosuppressive chemotherapy.1–3 The most serious complica-
tion of neutropenia is febrile neutropenia (FN), which is associated with an increased risk 
of morbidity and mortality as well as substantial cost of hospitalization and antibiotics.4 
Dose reductions and delays are common consequences of neutropenic events and may 
compromise the efficacy of chemotherapy in cancer patients for whom completion of all 
planned cycles is essential to achieve a maximum chance of treatment success.5
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Endogenous human G-CSF is a single polypeptide chain 
protein of 174 amino acids with O-glycosylation at one threo-
nine residue (molecular weight 18 kDa, carbohydrate moiety 
4% of total weight). It contains one free cysteinyl residue and 
two disulfide bonds. Cellular sources of G-CSF are monocytes, 
fibroblasts, and endothelial cells. The physiological role of 
G-CSF is to maintain neutrophil production during steady-
state conditions and to increase production during acute situ-
ations such as infection.6 The common mode of action is to 
mobilize hematopoietic progenitor cells into the peripheral 
circulation. Fully differentiated neutrophils are functionally 
activated by G-CSF.7 Owing to its hematopoietic activity, 
G-CSF was identified as potentially useful for the prevention 
and treatment of neutropenia and associated complications.8
Neupogen® (filgrastim; F. Hoffman-La Roche Ltd. [under 
licence of Amgen]-Basel-Switzerland) was the first therapeu-
tic recombinant G-CSF product approved by the US Food and 
Drug Administration (FDA). Filgrastim differs in structure 
from human G-CSF by lacking O-glycosylation and having an 
additional N-terminal methionine group as a result of bacterial 
expression, but it shows the same in vitro and in vivo activity 
as endogenous G-CSF. The main indication of filgrastim is 
to reduce the duration of neutropenia and the incidence of 
FN in patients receiving myelosuppressive chemotherapy.9 
Filgrastim is also approved to reduce the duration of neutro-
penia in patients undergoing myeloablative therapy followed 
by bone marrow transplantation who are considered to be 
at increased risk of prolonged severe neutropenia, to mobi-
lize peripheral blood progenitor cells (PBPCs), to increase 
neutrophil count, and to reduce the incidence and duration 
of infection-related events in neutropenic patients with an 
absolute neutrophil count (ANC) of ,0.5×109/L.8,9
After the expiration of the patent of filgrastim in 2006 
in Europe, several biosimilar versions of filgrastim have 
been approved by the European Medicines Agency (EMA) 
based on comparable quality, efficacy, and safety with the 
originator product.9 These products offer potential benefits 
by reducing health care costs and expanding access to these 
medications.8,10 Leucostim® (biosimilar filgrastim; Dong-A 
ST Co. Ltd., Daegu, South Korea) was the first biosimilar 
product approved by the Ministry of Health in Turkey and 
has been widely used across the country, since its launch in 
November 12, 2009. Biosimilar filgrastim has been on the 
market for .7 years and surpassed the use of the originator 
product in many hematology and oncology centers.
In the present study, as all biosimilars are unique, we 
aimed to investigate the bioequivalence of original filgrastim 
(Neupogen®) and biosimilar filgrastim (Leucostim®) by means 
of efficacy in treating neutropenia in cancer patients receiving 
chemotherapy. This study was partly presented as a poster 
presentation at the 9th National Medical Oncology Congress, 
September 12–16, 2012, Cyprus, and First Near East and 
Middle Asia Medical Oncology Associations (NEMA) Con-
gress, November 29–December 2, 2012, Istanbul, Turkey.
Patients and methods
study design and patient characteristics
This multicenter, observational study was conducted at 
14 centers in Turkey after receiving approval from the 
clinical trials ethics committee of Gaziantep University. 
The study included 337 patients who were receiving che-
motherapy for cancer and experienced neutropenia under 
chemotherapy during June 2011 and April 2012. Written 
informed consent has been obtained from all patients. For 
the treatment of neutropenia, patients were given either 
filgrastim 30 MIU or 48 MIU (Neupogen®) or biosimilar 
filgrastim 30 MIU (Leucostim®) until neutrophil recovery. 
Doses were calculated based on patients’ weight; however, 
it was at the discretion of the physician to administer 
original filgrastim 30 MIU or 48 MIU. Since this was an 
observational and multicenter study, medications given by 
the treating physicians were selected based on their own 
choices, according to the 2:1 ratio rule (66% vs 33%). At 
the end of the study, percentage allocations of patients into 
biosimilar filgrastim and original filgrastim treatments were 
61.9% and 38.1%, respectively. Furthermore, as this was an 
observational study, the study reflects routine clinical practice 
of the treating physician. Therefore, there were no exclusion 
criteria in the present study, except patients with comorbid 
diseases. Data regarding age, gender, weight, chemothera-
peutic agents used, the number of chemotherapy courses, 
previous diagnosis of neutropenia, neutrophil count of the 
patients before and after the treatment, medications used for 
the treatment of neutropenia, and the duration of neutropenia 
were collected. Patient demographics and blood counts at 
baseline are given in Tables 1 and 2. Time to ANC recovery 
was the primary efficacy measure. ANC recovery is defined 
as an ANC of $0.5×109/L (500 mm3) for three consecutive 
laboratory values obtained on different days. Date of ANC 
recovery is the date of the first of three consecutive labora-
tory values where ANC is $0.5×109/L (detailed information 
on ANC calculation can be obtained from the following 
website: https://www.cibmtr.org/manuals/fim/1/en/topic/
q8-11-initial-anc-recovery).
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Definition of primary prophylaxis
Primary prophylaxis is defined as patients receiving myelo-
toxic chemotherapy with curative intent and which has 
a documented incidence rate of febrile neutropenia (FN) 
of .20% or patients receiving myelotoxic chemotherapy 
with curative intent and which has a documented incidence 
rate of FN of 10%–20%, and one or more of the following 
pre-disposing patients’ risk factors: pre-existing neutropenia 
due to disease infiltration of bone marrow or other etiology, 
age .65 years, advanced disease stage, poor performance 
status, previous episodes of FN whilst receiving earlier che-
motherapy of a similar or lower dose intensity, extensive prior 
chemotherapy, previous irradiation to large volume of bone 
marrow, poor nutritional status, active infections or increased 
risk of infections, or serious co-morbidities.27
statistical analyses of data
Data were analyzed using the Statistical Package for the 
Social Sciences (SPSS) for Windows (SPSS Inc., Chicago, 
IL, USA). Descriptive statistics were presented as mean ± 
standard deviation or n (%), where applicable. While cat-
egorical independent variables were compared using the 
Pearson’s chi-square test, numerical independent variables 
were compared using the nonparametric Mann–Whitney 
U test. The nonparametric Wilcoxon signed-rank test was 
used for the comparison of neutrophil values before and after 
treatment. The Kruskal–Wallis one-way analysis of variance 
was used to test the difference between the three treatment 
arms. A p-value ,0.05 was considered as statistically 
significant.
ethical approval
The observational study was approved by the Turkish 
Ministry of Health under the number 048146.
Results
A total of 337 patients from 14 centers in Turkey were 
included in this observational study. The mean age of the 
patients was 53.15±14.10 years, and 51.0% were males. 
There was a significant difference between the age groups 
in terms of gender (p=0.021). The difference was attribut-
able to the higher number of males in the $65 years of age 
group; the majority of the patients $65 years of age were 
males (Table 1). Of the patients, 11.3% were hospitalized and 
45.1% were ambulatory patients, and 49.3% had a previous 
diagnosis of neutropenia. Cancer types in enrolled patients 
are presented in Table 3. Chemotherapy courses administered 
to patients enrolled are presented in Table 4. Allocation of 
chemotherapy courses per number of patients during the 
entire study is given in Table 5.
Neutropenia occurred during the first cycle of chemother-
apy in 13.7% (n=41) of the patients, during the second cycle 
of chemotherapy in 45.5% (n=136) of the patients, during the 
third cycle of chemotherapy in 27.4% (n=82) of the patients, 
during the fourth cycle of chemotherapy in 11.4% (n=34) 
Table 1 Patient demographics
Patient 
demographics
Filgrastim 
48 MIU 
(Neupogen®)
Filgrastim 
30 MIU 
(Neupogen®)
Biosimilar 
filgrastim 30 MIU 
(Leucostim®)
gender, n (%)
Females 51 (47.2) 20 (60.6) 114 (50)
Males 57 (52.8) 13 (39.4) 114 (50)
Total 108 (100) 33 (100) 228 (100)
age (total), years, n (%)
#50 46 (43) 17 (51.5) 82 (36)
51–64 39 (36.4) 10 (30.3) 92 (40.4)
$65 21 (20.6) 6 (18.2) 54 (23.6)
age (females), years, n (%)
#50 19 (38) 12 (60) 49 (42.9)
51–64 23 (36.4) 6 (30) 45 (39.6)
$65 8 (20.6) 2 (10) 20 (17.5)
age (males), years, n (%)
#50 27 (47.3) 5 (38.4) 33 (28.9)
51–64 16 (28.1) 4 (30.8) 47 (41.2)
$65 14 (24.6) 4 (30.8) 34 (29.9)
Weight, kg, n (%)
#70 32 (20.3) 16 (10.1) 110 (69.6)
$71 30 (32.3) 5 (5.4) 58 (62.4)
Total 62 (24.7) 21 (8.4) 168 (66.9)
Table 2 Blood counts at baseline
Blood counts Average
hematocrit (%)
Females (n=150) 30.1
Males (n=154) 31.8
rBc (106/µl)
Females (n=165) 3.5
Males (n=161) 3.66
WBc (103/µl)
Females (n=181) 1.82
Males (n=182) 1.86
PlT (103/µl)
Females (n=180) 174.3
Males (n=177) 152.3
neutrophils (103/µl)
Females (n=183) 1.14
Males (n=179) 0.48
Abbreviations: rBc, red blood cells; WBc, white blood cells; PlT, platelets.
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of the patients, and during the fifth cycle of chemotherapy 
in 2.0% (n=6) of the patients. The most commonly used 
chemotherapeutic agent was fluorouracil (14.6%), followed 
by cisplatin (13.3%) and doxorubicin (8.3%). All patients 
had a neutrophil count ,2.19 before filgrastim treatment. 
While the mean neutrophil count was 0.53±0.48 before 
treatment, a significant increase to 2.44±0.66 was observed 
after treatment (p=0.0001). While 90.3% of the patients had 
a neutrophil count ,1.49 before treatment, all patients had 
a neutrophil count $1.50 after treatment. Patients received 
either filgrastim 30 MIU, filgrastim 48 MIU, or biosimilar 
filgrastim 30 MIU for the treatment of their neutropenia 
(Table 6).
Neutropenia resolved within #4 days of filgrastim 
therapy in 60.1%, 56.7%, and 52.6% of the patients receiving 
biosimilar filgrastim 30 MIU, original filgrastim 30 MIU, 
and original filgrastim 48 MIU, respectively. However, 
there was no significant difference between the three arms 
in this respect (p=0.468; Table 7). Similarly, time to ANC 
recovery was comparable between the treatment arms 
(p=0.332; Table 8).
Although there was no significant difference between 
ambulatory patients receiving biosimilar filgrastim 30 MIU, 
original filgrastim 30 MIU and original filgrastim 48 MIU 
with respect to the time to ANC recovery (p=0.985), hospital-
ized patients receiving filgrastim 48 MIU had a significantly 
longer recovery period than those receiving biosimilar 
filgrastim 30 MIU and those receiving filgrastim 30 MIU 
(p=0.001; Table 9).
The mean duration of neutropenia was 5.75±4.92 days, 
5.26±3.89 days, and 5.62±4.83 days in the #50 years of 
age, 51–64 years of age, and $65 years of age groups, 
Table 3 cancer types in enrolled patients
Cancer type n % Cancer type n %
Breast 59 17.5 Bladder 2 0.6
lung 58 17.1 neuroendocrine 1 0.3
colorectal 46 13.6 Brain 2 0.6
Urogenital cancersa 43 12.7 Primary unknown 1 0.3
head and neckb 12 3.5 Malignant melanoma 2 0.6
liverc 11 3.3 Medulloblastoma 1 0.3
lymphomasd 36 10.5 adenoid cystic carcinoma 1 0.3
gastric 41 12.1 adenocarcinomasf 4 1.2
neuroectodermal 1 0.3 renal cell carcinoma 1 0.3
Mesenchymal 2 0.6 Parotid carcinoma 1 0.3
sarcomase 18 5.3 Pancreatic 7 2.07
Notes: aUrogenital cancers include cervical (n=4), ovarian (n=16), testicular (n=14), 
seminoma (n=4), endometrial (n=2), germ cell tumor (n=2), and uterus (n=1) 
cancers. bhead and neck includes esophageal (n=3), larynx (n=2), nasopharynx 
(n=2), and tongue (n=1) cancers. cliver includes hepatocellular carcinomas (n=4) 
and hepatoblastoma (n=1). dlymphomas include lymphoma (n=11), nh lymphoma 
(n=15), and hodgkin lymphoma (n=10). esarcomas include ewing’s sarcoma 
(n=2), leiomyosarcoma (n=1), Kaposi’s sarcoma (n=2), fibrosarcoma (n=1), 
liposarcoma (n=1), mezenchymal (n=2), osteosarcoma (n=4), synovial (n=1), soft 
tissue sarcoma (n=1), and uterus myosarcoma (n=3). fadenocarcinomas include 
adenocarcinoma (n=1), duodenal (n=1), prostatic (n=1), and gallbladder (n=1).
Abbreviation: nh, non-hodgkin’s.
Table 4 chemotherapy courses administered to patients enrolled
Chemotherapeutic 
agents
A B C D E Total %a
adriablastin 1 3 – – – 4 0.6
Bleomycin 6 9 1 – – 16 2.2
carboplatin 12 8 3 – 1 24 3.3
cisplatin 57 31 8 – – 96 13.3
Dacarbazine 1 – – 7 – 8 1.1
Dexamethasone 4 1 6 – – 11 1.5
Doxorubicin 13 30 12 2 3 60 8.3
Docetaxel 27 12 1 – – 40 5.5
epirubicin 4 6 3 – – 13 1.8
etoposide 2 33 7 2 – 44 6.1
Fluorouracil 52 23 30 1 – 106 14.6
Folinic acid 10 6 – 3 – 19 2.6
gemcitabine 11 10 – – – 21 2.9
ifosfamide 12 2 – 1 – 15 2.1
irinotecan 12 2 2 1 – 17 2.3
capecitabine 3 5 3 – – 11 1.5
Methotrexate 1 – – – – 1 0.1
Oxaliplatin 8 4 3 – – 15 2.1
Paclitaxel 13 7 1 1 – 22 3.0
Pemetrexed 2 – – – – 2 0.3
cyclophosphamide 14 20 10 2 – 46 6.4
cytarabin – 3 – – – 3 0.4
Tamoxifen 2 – – – – 2 0.3
UFT (tegafur/uracil) 1 – – – 1 0.1
Temozolomide 1 – – – 1 0.1
Topotecan – – 1 – – 1 0.1
Trastuzumab 4 5 1 – – 10 1.4
Vinblastine – – 7 – – 7 1.0
Vincristine 4 3 10 12 – 29 4.0
Vinorelbine 2 6 – – – 8 1.1
Zoledronic acid 1 – 2 – 1 4 0.6
Total 337 337 337 337 337 724 100.0
Notes: Definition of capital letters is as follows: A, one course of therapy; B, two 
courses of therapy; c, three courses of therapy; D, four courses of therapy; and 
E, five courses of therapy. aPercentage of column.
Table 5 allocation of chemotherapy courses per number of 
patients during the entire study
Number of courses n %
Patients received one course of therapy 41 13.7
Patients received two courses of therapy 136 45.5
Patients received three courses of therapy 82 27.4
Patients received four courses of therapy 34 11.4
Patients received five courses of therapy 6 2.0
Total 299 100.0
Table 6 Medications given for the treatment of neutropenia
Medication n %
Filgrastim 30 MiU 30 8.9
Biosimilar filgrastim 30 MIU 208 61.9
Filgrastim 48 MiU 98 29.2
Total 336 100.0
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respectively (p=0.99). The mean duration of neutropenia was 
5.08±3.70 days in male patients, while it was 6.02±5.25 days 
in female patients. There was no significant difference 
between genders in terms of the duration of neutropenia 
(p=0.57).
Among patients #70 kg, the percentage of those receiving 
biosimilar filgrastim 30 MIU was higher than the percentage 
of those receiving original filgrastim 30 MIU and 48 MIU. 
Similarly, the majority of patients $71 kg were receiving bio-
similar filgrastim 30 MIU. However, the difference between 
the groups did not reach statistical significance (p=0.06).
The duration of neutropenia was 5.62±4.63 days, 
6.00±5.75 days, and 5.67±3.75 days in patients #70 kg 
receiving biosimilar filgrastim 30 MIU, original filgrastim 
30 MIU, and original filgrastim 48 MIU, respectively. The 
duration of neutropenia was comparable between the three 
treatment arms (p=0.39; Table 10).
Discussion
Biosimilars are biological medicinal products derived from 
recombinant human DNA and expressed by genetically engi-
neered organisms to produce the target therapeutic proteins 
in large quantities. During the last few decades, including 
cytokines such as hematopoietic growth factors, interferons, 
and interleukins have received marketing authorization 
throughout the world. The term biosimilar is defined by the 
EMA along with the implementation of a specific regulatory 
framework for the marketing authorization of these products 
that are not identical to the innovator product because of 
inherent variability in the biological system and their com-
plex manufacturing process. Because of the lack of chemical 
identity due to minor differences in amino acid sequence or 
posttranscriptional glycosylation pattern, profile of different 
impurities, and excipients, some concerns have been raised 
by the medical community over the safety and efficacy of 
biosimilars as these may lead to increased immunogenicity, 
which in turn results in safety and efficacy problems.11,12 
Therefore, it must be shown by preapproval non-clinical and 
clinical studies that any differences in quality attributes have 
no impact on the efficacy and safety of the product.11
Clinical studies on filgrastim biosimilars have shown that 
these products are as safe and effective as original filgrastim 
in reducing the duration of severe neutropenia and the inci-
dence of FN in different cancer settings.13–15 In their study 
on breast cancer patients receiving docetaxel/doxorubicin 
chemotherapy, del Giglio et al13 reported the mean duration 
of severe neutropenia to be 1.1 days during the first cycle of 
chemotherapy regimen both in Tevagrastim® (XM02) and 
filgrastim groups when the drugs were administered 24 hours 
after chemotherapy for at least 5 days and a maximum of 
14 days. In the first cycle of chemotherapy, the incidence of 
FN was 12.1% and 12.5% in the XM02 and filgrastim groups, 
respectively. The authors observed no significant differences 
between the two treatment groups in terms of the incidence 
of FN, neither in the first cycle nor across all cycles of che-
motherapy. Similarly, the mean time to ANC recovery in the 
first cycle was 8.0 and 7.8 days in the XM02 and filgrastim 
groups, respectively.13 Another study under the same clinical 
development program on patients with non-Hodgkin’s (NH) 
lymphoma receiving CHOP (Cyclophosphamide Doxorubicin 
[Hydroxydaunomycin] Vincristine Prednisolone) therapy 
Table 7 Percentage of patients recovered from neutropenia 
within #4 days and the percentage of those recovered from 
neutropenia within $5 days
Medication Time to ANC recovery (days)
$5 days, n (%) #4 days, n (%) Total
Filgrastim 30 MiU 13 (43.3) 17 (56.7) 30
Biosimilar filgrastim 30 MIU 79 (39.9) 119 (60.1) 198
Filgrastim 48 MiU 46 (47.4) 51 (52.6) 97
Total 138 (42.5) 187 (57.5) 325
Note: compared using the chi-square test.
Abbreviation: anc, absolute neutrophil count.
Table 8 Time to anc recovery
Medication Mean ± SD Median (min–max)
Filgrastim 30 MiU 5.66±4.83 3.5 (2–21)
Biosimilar filgrastim 30 MIU 5.41±4.54 4 (1–21)
Filgrastim 48 MiU 5.63±4.32 4 (1–21)
Note: Compared using Kruskal–Wallis one-way analysis of variance.
Abbreviations: anc, absolute neutrophil count; sD, standard deviation; min, 
minimum; max, maximum.
Table 9 Time to anc recovery in hospitalized patients
Medication Mean ± SD Median (min–max)
Filgrastim 30 MiU 3.70±2.18 3 (1–12)
Biosimilar filgrastim 30 MIU 5.09±5.78 2 (2–21)
Filgrastim 48 MiU 5.70±4.20 5 (1–21)
Note: Compared using Kruskal–Wallis one-way analysis of variance.
Abbreviations: anc, absolute neutrophil count; sD, standard deviation; min, 
minimum; max, maximum.
Table 10 Duration of neutropenia in patients #70 kg
Medication Duration of neutropenia, mean ± SD, 
median (min–max)
Biosimilar filgrastim 30 MIU 5.62±4.63, 4 (1–21)
Filgrastim 30 MiU 6.00±5.75, 3 (2–21)
Filgrastim 48 MiU 5.67±3.75, 5 (2–21)
Note: Compared using the Kruskal–Wallis test.
Abbreviations: sD, standard deviation; min, minimum; max, maximum.
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reported the mean duration of severe neutropenia to be 0.5 
and 0.9 days in the first cycle in the XM02 and filgrastim 
groups, respectively.16 In that particular study, the incidence 
of FN in the first chemotherapy cycle was 11.1% and 20.7% 
in the XM02 and filgrastim groups, respectively. The third 
study in the program conducted on cancer patients with small 
cell or non-small-cell lung cancer receiving platinum-based 
chemotherapy reported a mean duration of severe neutro-
penia in the first cycle of chemotherapy of 0.5 and 0.3 days 
in the XM02 and filgrastim groups, respectively.14 Similar 
to the abovementioned studies, the two treatment groups 
were comparable in terms of the incidence of FN in the first 
cycle of chemotherapy (15.0% vs 8.8%, p=0.2347). A meta-
analysis was conducted using the data of these three studies to 
compare XM02 and filgrastim in terms of their prophylactic 
effect on the development of FN during the first cycle of 
chemotherapy in relation to the myelotoxic potency of che-
motherapy regimen.16 Patients were allocated to one of the 
following chemotherapy categories: docetaxel–doxorubicin, 
CHOP/Pt-vinorelbine or Pt-vinblastine/Pt-etoposide, and 
Pt-gemcitabine/Pt-docetaxel or Pt-paclitaxel. The incidence 
of FN in the first cycle of chemotherapy was low (ranged 
between 12% and 16%), and the authors concluded that the 
incidence of FN was not directly correlated with the myelo-
toxic potency of chemotherapy regimen.15
A more recent study comparing filgrastim and its biosimi-
lar Nivestim® (Hospira Zagreb, Prigorje Brdovecko, Crotia) 
in a breast cancer setting reported the mean duration of severe 
neutropenia in the first cycle of chemotherapy to be 1.6 and 
1.3 days in the Nivestim® and filgrastim groups, respectively. 
Furthermore, the incidence of severe neutropenia in the first 
cycle was comparable between the two groups (77.6% and 
68.2%). During the subsequent cycles of chemotherapy, the 
incidence of severe neutropenia remained similar between the 
two groups. The incidence of FN in cycles 1–3 was 2.4% in 
both treatment groups. The Nivestim® and filgrastim groups 
were also comparable with respect to the mean duration to 
ANC recovery. The mean time to ANC recovery in the first 
chemotherapy cycle was 7.8 days in both groups.8
In the present study, secondary prophylaxis with bio-
similar filgrastim provided a similar degree of hemopoietic 
support with respect to the time to ANC recovery as compared 
with original filgrastim. The mean time to ANC recovery was 
5.41±4.54 days, 5.66±4.83 days, and 5.63±4.32 days in the 
biosimilar filgrastim 30 MIU, original filgrastim 30 MIU, and 
original filgrastim 48 MIU groups, respectively.
Although all patients have a risk for developing neutropenia 
and its complications while receiving chemotherapy, patients 
at greater risk can be predicted based on several risk factors 
such as the use of some specific classes of chemotherapy 
regimen and the phase of therapy. A study on elderly patients 
with aggressive NH lymphoma receiving doxorubicin-based 
chemotherapy reported that 63% of the toxic deaths occurred 
after the first cycle of chemotherapy.17 In a study on patients 
with intermediate-grade, NH lymphoma receiving CHOP 
chemotherapy, febrile neutropenic event occurred during 
the first cycle in one-half of 160 patients experiencing FN.18 
Moreover, in a retrospective study on 1,355 patients with 
intermediate-grade NH lymphoma, more than one-half 
of all initial hospitalizations for FN occurred in the first 
or second cycle of chemotherapy.19 A more recent study 
reported that ~60% of febrile neutropenic events occurred 
during the first cycle of therapy.20 In accordance with the 
literature, ~60% of neutropenic events were noted during the 
first two cycles of chemotherapy in the present study.
The chemotherapy regimen is one of the primary deter-
minants of the risk of neutropenia, and some chemotherapy 
regimens are more myelotoxic than others.5,21,22 High doses 
of cyclophosphamide or the use of etoposide in patients with 
NH lymphoma,23,24 as well as high doses of anthracyclines in 
patients with early breast cancer,25 have been identified as sig-
nificant predictors of neutropenic complications. Recently, a 
multivariate model of risk developed using the data of patients 
with solid tumors or malignant lymphoma showed that the 
use of several classes of chemotherapeutic agents, including 
the anthracyclines, taxanes (paclitaxel and docetaxel), certain 
alkylating agents (cyclophosphamide and ifosfamide), type I 
and type II topoisomerase inhibitors, platinums (cisplatin and 
carboplatin), gemcitabine, and vinorelbine, were associated 
with an increased risk of neutropenic events.26 However, 
a meta-analysis of three bioequivalence studies found no 
direct correlation between the development of neutropenic 
events and myelotoxic potency of chemotherapy regimen in 
patients with NH lymphoma.16 However, in that particular 
study, the comparison was made between three chemotherapy 
regimens that were associated with a high risk of neutropenic 
events. In this study, the most commonly used chemo-
therapeutic agent was fluorouracil, followed by cisplatin and 
doxorubicin. The common use of these agents might have 
contributed to the development of neutropenia in our patients.
Conclusion
The results of this observational study indicate that original 
filgrastim and biosimilar filgrastim have comparable efficacy in 
treating neutropenia in patients receiving cancer chemotherapy. 
Biosimilar filgrastim provides a valuable alternative to original 
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filgrastim; however, there is need for further studies comparing 
the two products in different patient subpopulations.
Disclosure
The authors report no conflicts of interest in this work.
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